0001213900-26-055769
SEC filingOruka Therapeutics reported wider operating and net losses in Q1 FY2026 versus prior year, reflecting continued strategic investment in clinical development; free cash flow deterioration aligns with elevated operating outflows, consistent with the company’s stated trajectory of substantial near-term losses.
Operating income for Q1 FY2026 was -$36.4 million, compared to -$25.1 million in Q1 FY2025 — a 45.2% year-over-year deterioration. Net income was -$31.8 million, versus -$21.0 million in the prior-year quarter, representing a 51.5% decline. These widening losses reflect the company’s continued prioritization of clinical advancement across its pipeline, consistent with its stated strategy of investing to de-risk long-term value. Management has explicitly noted it expects to incur substantial losses for the foreseeable future, with profitability contingent upon successful development, regulatory approval, and commercialization of its product candidates.
Diluted EPS for Q1 FY2026 was $-0.48, compared to $-0.40 in Q1 FY2025 — a 20.0% decline. This reflects both the increase in net loss magnitude and growth in weighted-average diluted shares outstanding, which is aligned with equity-based compensation practices supporting R&D expansion.